PF-Atlas › Clinical Trials › NCT06588686
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Buloxibutid · Phase 2
Registry ID
NCT06588686
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Buloxibutid
Sponsor
Vicore Pharma AB
Enrollment
378
Locations
104
About this trial
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06588686 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.